Skip to main
PSTV
PSTV logo

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc has experienced a significant increase in cash and investments, reaching $16.6 million, bolstered by advances from the Cancer Prevention and Research Institute of Texas (CPRIT) and strong market activities, which have aided the company's compliance with Nasdaq listing standards. The company is advancing its CNSide Diagnostic platform, enhancing its manufacturing capability and commercial readiness, while also benefiting from interest from NCI-Designated Cancer Centers, indicating a strong adoption potential in the market. Furthermore, Plus Therapeutics's operational advancements, including receiving a substantial grant for leptomeningeal metastases research and achieving CLIA certification for its laboratory, solidify its future growth prospects and reimbursement infrastructure.

Bears say

Plus Therapeutics Inc reported grant revenue of $1.4 million but experienced a significant total operating loss of $4.5 million, culminating in a net loss of $4.4 million. The company faces several risks that could hinder its financial stability, including the potential failure of its product candidates to demonstrate safety and efficacy in clinical trials, challenges in gaining regulatory approval, and competition within the market. Additionally, the pro forma EPS of $0.02 contrasted starkly with estimates of $(0.13) and consensus expectations of $(0.12), indicating a gap that raises concerns regarding the company's financial performance and outlook.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.